Last reviewed · How we verify
AstraZeneca — Portfolio Competitive Intelligence Brief
AZN (NASDAQ)
120 marketed
0 filed
155 Phase 3
111 Phase 2
303 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Wainua | EPLONTERSEN | marketed | Transthyretin-directed RNA Interaction [EPC] | Neuroscience | 2025-01-01 | |
| Beyfortus | NIRSEVIMAB | marketed | Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC] | RSV | Infectious Disease | 2023-01-01 |
| Imjudo | TREMELIMUMAB | marketed | CTLA-4-directed Blocking Antibody [EPC] | CTLA-4 | Oncology | 2022-01-01 |
| Tezspire | AMG 157 | marketed | Thymic Stromal Lymphopoietin Blocker [EPC] | Thymic stromal lymphopoietin | Respiratory | 2021-01-01 |
| Tezspire | TEZEPELUMAB | marketed | Thymic Stromal Lymphopoietin Blocker [EPC] | 2021-01-01 | ||
| Saphnelo | ANIFROLUMAB | marketed | Type I Interferon Receptor Antagonist [EPC] | Interferon alpha/beta receptor 1 | Immunology | 2021-01-01 |
| Koselugo | selumetinib | marketed | Kinase Inhibitor [EPC] | AP2-associated protein kinase 1 | Oncology | 2020-01-01 |
| Ultomiris | RAVULIZUMAB | marketed | Complement Inhibitor [EPC] | Complement C5 | Cardiovascular | 2018-01-01 |
| Lumoxiti | MOXETUMOMAB PASUDOTOX | marketed | B-cell receptor CD22 | Oncology | 2018-01-01 | |
| Fasenra | BENRALIZUMAB | marketed | Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC] | Interleukin-5 receptor subunit alpha | Immunology | 2017-01-01 |
| Imfinzi | durvalumab | marketed | Programmed Death Ligand-1 Blocker [EPC] | Programmed cell death 1 ligand 1 | Oncology | 2017-01-01 |
| Calquence | ACALABRUTINIB | marketed | Kinase Inhibitor [EPC] | Tyrosine-protein kinase BTK | Oncology | 2017-01-01 |
Therapeutic area mix
- Oncology · 114
- Respiratory · 34
- Diabetes · 27
- Immunology · 20
- Cardiovascular · 17
- Respiratory / Pulmonology · 13
- Metabolic · 12
- Other · 12
- Psychiatry · 11
- Respiratory/Pulmonology · 11
Recent regulatory actions (last 90 days)
- — Beyfortus · FDA · approved · US
- — Farxiga · FDA · approved · US
- — Farxiga · FDA · approved · US
- — Farxiga · FDA · approved · US
- — Farxiga · FDA · approved · US
- — dapagliflozin and saxagliptin · FDA · approved · US
- — Farxiga · FDA · approved · US
- — Tracleer · FDA · approved · US
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Tracleer · 8309126 · Formulation · US
- — Byetta · 8329648 · US
- — Byetta · 8906851 · US
- — Byetta · 9884092 · US
- — Pulmicort Respules · 11413296 · Formulation · US
- — Pulmicort Respules · 8497258 · Method of Use · US
- — Pulmicort Respules · 11197822 · Formulation · US
- — Pulmicort Respules · 9119863 · Method of Use · US
- — Pulmicort Respules · 8975243 · Method of Use · US
- — Pulmicort Respules · 8679545 · Formulation · US
- — Koselugo · 9562017 · US
- — Koselugo · 9156795 · US
- — Byetta · 8329648*PED · US
- — Byetta · 9884092*PED · US
- — Byetta · 8906851*PED · US
- — Byetta · 8501698 · US
- — Byetta · 8758292 · US
- — Byetta · 8501698*PED · US
- — Tracleer · 7959945 · Formulation · US
- — Byetta · 8216180 · US
- — Byetta · 8361972 · US
- — Byetta · 9320853 · US
- — Byetta · 8439864 · US
- — Byetta · 8758292*PED · US
- — Byetta · 8216180*PED · US
- — Byetta · 8361972*PED · US
- — Byetta · 9320853*PED · US
- — Byetta · 8439864*PED · US
- — Pulmicort Respules · 11357859 · Method of Use · US
- — Pulmicort Respules · 10293052 · Formulation · US
Competitive overlap (companies sharing drug classes)
- GlaxoSmithKline · 25 shared drug classes
- Sanofi · 18 shared drug classes
- Pfizer · 16 shared drug classes
- Sun Yat-sen University · 10 shared drug classes
- · 10 shared drug classes
- Merck Sharp & Dohme LLC · 10 shared drug classes
- Jiangsu HengRui Medicine Co., Ltd. · 9 shared drug classes
- Novartis · 9 shared drug classes
Subscribe to ongoing alerts
Every new pipeline event for AstraZeneca:
- AstraZeneca pipeline updates — RSS
- AstraZeneca pipeline updates — Atom
- AstraZeneca pipeline updates — JSON
Cite this brief
Drug Landscape (2026). AstraZeneca — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/astrazeneca. Accessed 2026-05-13.